INmune Bio Raises Important Funding Through Direct Offering
INmune Bio Inc. (NASDAQ: INMB), an innovative biotechnology firm in the clinical stage, has recently revealed that it successfully secured $13.0 million in gross proceeds via a registered direct offering. This substantial funding will support their ongoing mission to create groundbreaking treatments that leverage the innate immune system to target various diseases.
Details of the Offering
The company has formed agreements with both new and existing institutional investors, as well as certain insiders like directors, officers, and employees. This agreement involves the offering of a total of 2,341,260 shares of common stock, along with warrants that permit the purchase of an equal number of shares. Institutional investors will acquire these shares and warrants at an appealing price of $5.50, while insiders will pay a higher price of $6.50 per share.
Understanding How Warrants Work
The associated warrants give investors the option to purchase shares starting six months after they are issued, with a strike price set at $6.40. These warrants will be valid for five years from their first exercise date, although their timelines may be expedited if certain conditions are met. For insiders, if the warrant's expiration coincides with a blackout period, an additional 60 days will be provided after the blackout for exercising the warrants.
Planned Use of Proceeds
The proceeds from this offering are earmarked for working capital and overall corporate needs, giving INmune Bio a strong financial base to accelerate its growth initiatives. The expected closing date for the offering is around September 16, 2024, pending the usual closing conditions being satisfied.
A.G.P./Alliance Global Partners' Role
A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering, playing an essential role in facilitating this critical financial transaction.
About INmune Bio Inc.
INmune Bio is committed to developing cutting-edge therapies designed to harness the body's natural immune defenses. Currently, the company is advancing two robust product platforms through clinical trials. Their initial platform, the Dominant-Negative Tumor Necrosis Factor (DN-TNF), aims to neutralize soluble TNF, a vital component in immune dysfunction linked to various diseases. Among these treatments is XPRO, which is in trials geared towards addressing Mild Alzheimer’s disease.
Broader Therapeutic Applications
Besides Alzheimer’s, INmune Bio is investigating solutions for conditions including treatment-resistant depression and cancer, as resources allow. Their second platform focuses on optimizing the Natural Killer (NK) cell system through INKmune™, a precision medicine designed to train NK cells to effectively fight cancer. Currently, INKmune is undergoing a Phase I/II trial in the United States, targeting patients with metastatic castrate-resistant prostate cancer.
The Future for INmune Bio
As INmune Bio progresses through its clinical trials, the company is positioning itself at the forefront of immune-centered therapies that could transform treatment strategies. The funding obtained from this offering will significantly enhance their capacity to complete clinical trials and hasten their journey to market.
Frequently Asked Questions
What will the $13 million raised by INmune Bio be used for?
The funds will primarily support working capital and general corporate objectives, assisting in the advancement of their therapeutic development programs.
Which key products is INmune Bio focused on developing?
INmune Bio is working on significant therapies such as XPRO for Alzheimer’s disease and INKmune for cancer treatment.
Who are the main investors in this offering?
The offering involves new and existing institutional investors, along with insiders from the company.
What terms come with the warrants issued in this offering?
The warrants enable the purchase of shares at a price of $6.40, starting six months after issuance, and they will be valid for five years.
What role does A.G.P./Alliance Global Partners play?
A.G.P./Alliance Global Partners is the sole placement agent for the offering, helping to facilitate the transaction's completion.
